Inhibitors of the peptidyl-prolyl cis/trans isomerase (PIN1), combinations and uses thereof
AssigneesDana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc., Yeda Research and Development Co. Ltd.
InventorsShizhong Ke, Gerburg Wulf, Xiao Zhen Zhou, Nir London, Wenyi Wei, Kun Ping Lu, Nathanael S. Gray, Behnam Nabet
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof.
Claims21
A method of treating a disease or disorder mediated by dysregulated cyclin-dependent kinase 4/6 (CDK4/6) activity, in a subject in need thereof, or a method of reducing the activity of CDK4/6 in a cell, either in vivo or in vitro,
- comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitors, or a pharmaceutically acceptable salt or salts thereof.
A pharmaceutical composition, comprising a therapeutically effective amount of one or more CDK4/6 inhibitors, wherein the one or more CDK4/6 inhibitors is palbociclib, abemaciclib, ribociclib, or a combination thereof, and a therapeutically effective amount of one or more Pin1 inhibitors, wherein the one or more Pin1 inhibitors is sulfopin, ATRA, ATO, or a combination thereof, or a pharmaceutically acceptable salt or stereoisomer thereof.
Dependencies are inferred from the claim text.